0
61
Psychiatric News   |   March 02, 2001 
Volume 36 Number 5 page 37-37
Letter to the Editor
  • Print
  • E-mail
    Recipient(s) will receive an email with a link (good for 72 hours) to 'Only Marketing Information' and do not need to have Psychiatric News account to access the content.
    Example: John Doe
    CC Me:
    Enter your valid email address. Example: jdoe@example.com
    Separate multiple email address with semi-colons (up to 5).
    's Psychiatric News: 'Only Marketing Information'
    Subject for your email.
    (Optional, message will truncate at 1000 characters)
    Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.
    Copyright © American Psychiatric Association. All rights reserved.
  • Share
  • Reprints
Only Marketing Information
Edward Gordon, M.D.
text A A A
We are accustomed to utilizing the Physicians’ Desk Reference (PDR) as a reference source. However, it is a highly incomplete reference source, compiled, as it were, with materials supplied by drug companies for a fee. It is, therefore, a widely distributed source of advertising information.
Some commonly utilized medications are not even present in the PDR, likely because the medications are off patent and the manufacturers choose not to pay the fees required for listing.
Psychiatrists attempting to find trazodone (Desyrel) and fluphenazine (Prolixin) listed will have a futile search, despite the fact that both of these are stalwarts of modern psychiatry, with fluphenazine being frequently used for chronic schizophrenia patients whose medication compliance is unreliable. Trazodone is used both as a supplemental antidepressant and, especially by primary care physicians, as a nonaddicting sedative.
The PDR serves only to list FDA-approved material. As such, it bears little resemblance to a reference source as it fails to indicate common, off-label (state-of-the-art) uses by psychiatrists in daily practice.

Interactive Graphics

Video

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Similar Articles
PSYCHIATRIC NEWS
Articles
Reasons for Lower-Than-Expected Enrollment in PCIPs
Psychiatric News 21 October 2011: Vol. 46. no. 20, pp. 12-12
Drug Firm to Pay Huge Fine in Illegal Marketing Case
Psychiatric News 15 April 2011: Vol. 46. no. 8, pp. 9-9
M.D.s Can Deny Marketers Access to Prescribing Data, Court Rules
Psychiatric News 3 September 2010: Vol. 45. no. 17, pp. 1-26
[+] View More
Copyright ©
American
Psychiatric
Association